At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy, Safety and Pharmacokinetics of Ascending Dosages of Moxidectin Alone and in Comparison to Ivermectin Against Strongyloides Stercoralis in Adults: a Randomized Controlled Trial
In Brief
A Phase 3 clinical trial evaluating Moxidectin, Ivermectin, and 1 other intervention for Strongyloides Stercoralis Infection. Completed, enrolled 617 participants across 1 site.
Detailed Summary
This study is a phase 2, blinded and randomized clinical trial. The phase 2a trial is single blinded and conducted in Lao, while the phase 2b trial is double-blinded and conducted in Lao and Cambodia. The study aims at providing evidence on effective doses and safety of moxidectin in adults against infection with S. stercoralis in Laos (trial 2a) and efficacy and safety of moxidectin compared to ivermectin in adults against infection with S. stercoralis in Laos and Cambodia (trial 2b). The efficacy of the treatment will be assessed by collecting three stool samples once pre-treatment and once 21 days post-treatment. The stool samples will be analyzed by a quantitative Baermann assay.
Study Details
Timeline
Interventions
Monotherapy, oral administration, single dose, fixed dose
Monotherapy, oral administration, single dose, weight dependent
Monotherapy, oral administration, single dose, matching number of tablets